Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FABP6 | P51161 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL993246 | 0.88 | GAA (0.46) | GAAALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL4621927 | 0.85 | FABP6 (0.35) | GAAALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL4198 | 0.85 | — | — | |
| SCHEMBL969300 | 0.85 | — | — | |
| SCHEMBL29186798 | 0.85 | GAA (0.38) | GAAALDH1A1SMN1; SMN2HTTLMNA | |
| Fluoride SCHEMBL27461973 | 0.85 | — | — | |
| SCHEMBL80643 | 0.85 | — | — | |
| Morpholine SCHEMBL28460086 | 0.84 | GAA (0.50) | GAASMN1; SMN2HTTLMNAMEN1 | |
| SCHEMBL6678827 | 0.83 | — | — | |
| SCHEMBL1969512 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005113520-A1 | SUBSTITUTED 2,3,5-TRIFLUORPHENYL OXAZOLIDINONES FOR USE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-12-01 | — | — | WO | disclosed |